Amneal Pharmaceuticals has received FDA approval with Competitive Generic Therapy designation for lanreotide injection 120 mg/0.5 mL, supplied in a sterile, single-dose prefilled syringe. The product is now available to order through wholesalers. With dedicated, large-scale, in-house manufacturing capacity, Amneal aims to be well positioned to reliably supply the market and broaden access to this medicine.